Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy.
Tachycardia-induced cardiomyopathy is characterized by ventricular systolic dysfunction and congestive heart failure resulting from persistent or highly frequent tachyarrhythmias with uncontrolled heart rate. While reversible and often considered benign, few studies have examined the outcome of the disorder. The clinical characteristics, treatment, and long-term outcomes of 12 consecutive patients with tachycardia-induced cardiomyopathy (9 men, age, 51.9 +/- 17.6 years) were studied. The mean period between the occurrence of tachyarrhythmias and the development of congestive heart failure was 26.0 +/- 34.3 days. The mean heart rate on admission was 156.3 +/- 28.7 beats/min. All patients had severe heart failure with a NYHA functional class of 2.3 +/- 0.5, left ventricular ejection fraction of 0.32 +/- 0.10, and brain natriuretic peptide level of 505.7 +/- 449.1 pg/mL. In all patients, cardiac dysfunction recovered after 53.5 +/- 61.3 days. During the follow-up of 53 +/- 24 months, 2 patients had a recurrence of heart failure with uncontrolled tachyarrhythmia and 1 patient died suddenly. In tachycardia-induced cardiomyopathy, recurrent heart failure with uncontrollable tachyarrhythmia and sudden death were observed after recovery from cardiac dysfunction. A substrate for heart failure and/or life-threatening arrhythmia might persist, and careful, long-term follow-up seems required.
Watanabe
Hiroshi
H
Division of Cardiology, Niigata University Graduate School of Medical and Dental Science., Niigata, Japan.
Okamura
Kazuki
K
Chinushi
Masaomi
M
Furushima
Hiroshi
H
Tanabe
Yasutaka
Y
Kodama
Makoto
M
Aizawa
Yoshifusa
Y
D000328:Adult; D000368:Aged; D009202:Cardiomyopathies / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D016757:Death, Sudden, Cardiac; D005260:Female; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D012008:Recurrence; D013318:Stroke Volume / Q000502:physiology; D013610:Tachycardia / Q000150:complications* / Q000628:therapy; D016896:Treatment Outcome; D018754:Ventricular Dysfunction / Q000209:etiology
D020097:Natriuretic Peptide, Brain